Clinical Trial Update: Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating short-term preoperative enzalutamide, alone or with exemestane, in primary breast cancer (ER-positive and AR-positive cohorts).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Xtandi (enzalutamide)

Snippet

Sponsor: Queen Mary University of London | Conditions: Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN | Phase 2 | Status: COMPLETED